Top

Inflammation Research

Published in:

05-09-2022 | Review

The role of adenosine A₁ receptor on immune cells

Authors: Lingyu Zhong, Qiao Peng, Xun Zeng

Published in: Inflammation Research | Issue 10-11/2022

Abstract

Background

Adenosine, acting as a regulator by mediating the activation of G protein-coupled adenosine receptor families (A₁, A₂A, A₂B, and A₃), plays an important role under physiological and pathological conditions. As the receptor with the highest affinity for adenosine, the role of adenosine A₁ receptor (A₁R)-mediated adenosine signaling pathway in the central nervous system has been well addressed. However, functions of A₁R on immune cells are less summarized. Considering that some immune cells express multiple types of adenosine receptors with distinct effects and varied density, exogenous adenosine of different concentrations may induce divergent immune cell functions.

Materials and methods

The literatures about the expression of A₁R and its regulation on immune cells and how it regulates the function of immune cells were searched on PubMed and Google Scholar.

Conclusion

In this review, we discussed the effects of A₁R on immune cells, including monocytes, macrophages, neutrophils, dendritic cells, and microglia, and focused on the role of A₁R in regulating immune cells in diseases, which may facilitate our understanding of the mechanisms by which adenosine affects immune cells through A₁R.

Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006;5:247–64. https://doi.org/10.1038/nrd1983.CrossRefPubMedPubMedCentral

Stagg J, Smyth MJ. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene. 2010;29:5346–58. https://doi.org/10.1038/onc.2010.292.CrossRefPubMed

Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE. International union of basic and clinical pharmacology. LXXXI. Nomenclature and classification of adenosine receptors—an update. Pharmacol Rev. 2011;63:1–34. https://doi.org/10.1124/pr.110.003285.CrossRefPubMedPubMedCentral

Allard B, Allard D, Buisseret L, Stagg J. The adenosine pathway in immuno-oncology. Nat Rev Clin Oncol. 2020;17:611–29. https://doi.org/10.1038/s41571-020-0382-2.CrossRefPubMed

Borea PA, Gessi S, Merighi S, Vincenzi F, Varani K. Pharmacology of adenosine receptors: the state of the art. Physiol Rev. 2018;98:1591–625. https://doi.org/10.1152/physrev.00049.2017.CrossRefPubMed

Borea PA, Gessi S, Merighi S, Vincenzi F, Varani K. Pathological overproduction: the bad side of adenosine. Br J Pharmacol. 2017;174:1945–60. https://doi.org/10.1111/bph.13763.CrossRefPubMedPubMedCentral

Franco R, Cordomí A, Llinas del Torrent C, Lillo A, Serrano-Marín J, Navarro G, Pardo L. Structure and function of adenosine receptor heteromers. Cell Mol Life Sci. 2021;78:3957–68. https://doi.org/10.1007/s00018-021-03761-6.CrossRefPubMed

Chen JF, Eltzschig HK, Fredholm BB. Adenosine receptors as drug targets-what are the challenges? Nat Rev Drug Discov. 2013;12:265–86. https://doi.org/10.1038/nrd3955.CrossRefPubMedPubMedCentral

Modlinger PS, Welch WJ. Adenosine A1 receptor antagonists and the kidney. Curr Opin Nephrol Hypertens. 2003;12:497–502. https://doi.org/10.1097/00041552-200309000-00003.CrossRefPubMed

10.

Nadeem A, Obiefuna PCM, Wilson CN, Mustafa SJ. Adenosine A1 receptor antagonist versus montelukast on airway reactivity and inflammation. Eur J Pharmacol. 2006;551:116–24. https://doi.org/10.1016/j.ejphar.2006.08.059.CrossRefPubMedPubMedCentral

11.

Kashfi S, Ghaedi K, Baharvand H, Nasr-Esfahani MH, Javan M. A1 adenosine receptor activation modulates central nervous system development and repair. Mol Neurobiol. 2017;54:8128–39. https://doi.org/10.1007/s12035-016-0292-6.CrossRefPubMed

12.

Liu YJ, Chen J, Li X, Zhou X, Hu YM, Chu SF, Peng Y, Chen NH. Research progress on adenosine in central nervous system diseases. CNS Neurosci Ther. 2019;25:899–910. https://doi.org/10.1111/cns.13190.CrossRefPubMedPubMedCentral

13.

Bours MJL, Swennen ELR, Di Virgilio F, Cronstein BN, Dagnelie PC. Adenosine 5’-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther. 2006;112:358–404. https://doi.org/10.1016/j.pharmthera.2005.04.013.CrossRefPubMed

14.

Ren H, Stiles GL. Characterization of the human A1 adenosine receptor gene. Evidence for alternative splicing. J Biol Chem. 1994;269:3104–10. https://doi.org/10.1016/s0021-9258(17)42054-0.CrossRefPubMed

15.

Glukhova A, Thal DM, Nguyen AT, Vecchio EA, Jörg M, Scammells PJ, May LT, Sexton PM, Christopoulos A. Structure of the adenosine A1 receptor reveals the basis for subtype selectivity. Cell. 2017;168:867-877.e13. https://doi.org/10.1016/j.cell.2017.01.042.CrossRefPubMed

16.

Jespers W, Schiedel AC, Heitman LH, Cooke RM, Kleene L, van Westen GJP, Gloriam DE, Müller CE, Sotelo E, Gutiérrez-de-Terán H. Structural mapping of adenosine receptor mutations: ligand binding and signaling mechanisms. Trends Pharmacol Sci. 2018;39:75–89. https://doi.org/10.1016/j.tips.2017.11.001.CrossRefPubMed

17.

Klinger M, Freissmuth M, Nanoff C. Adenosine receptors: G protein-mediated signalling and the role of accessory proteins. Cell Signal. 2002;14:99–108. https://doi.org/10.1016/S0898-6568(01)00235-2.CrossRefPubMed

18.

Effendi WI, Nagano T, Kobayashi K, Nishimura Y. Focusing on adenosine receptors as a potential targeted therapy in human diseases. Cells. 2020;9:1–36. https://doi.org/10.3390/cells9030785.CrossRef

19.

Defer N, Best-belpomme M, Hanoune J, Cre F, Best-belpomme M, Hanoune J, Sutherland E. Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase. Am J Physiol Ren Physiol. 2000;279:400–16. https://doi.org/10.1152/ajprenal.2000.279.3.F400.CrossRef

20.

Liu AMF, Wong YH. G16-mediated activation of nuclear factor κB by the adenosine A1 receptor involves c-Src, protein kinase C, and ERK signaling*. J Biol Chem. 2004;279:53196–204. https://doi.org/10.1074/jbc.M410196200.CrossRefPubMed

21.

Schulte G, Fredholm BB. Human adenosine A1, A(2A), A(2B), and A3 receptors expressed in Chinese hamster ovary cells all mediate the phosphorylation of extracellular-regulated kinase 1/2. Mol Pharmacol. 2000;58:477–82. https://doi.org/10.1124/mol.58.3.477.CrossRefPubMed

22.

Faure M, Voyno-Yasenetskaya TA, Bourne HR. cAMP and βγ subunits of heterotrimeric G proteins stimulate the mitogen- activated protein kinase pathway in COS-7 cells. J Biol Chem. 1994;269:7851–4. https://doi.org/10.1016/s0021-9258(17)37127-2.CrossRefPubMed

23.

Schulte G, Fredholm BB. Signalling from adenosine receptors to mitogen-activated protein kinases. Cell Signal. 2003;15:813–27. https://doi.org/10.1016/S0898-6568(03)00058-5.CrossRefPubMed

24.

Deb PK, Deka S, Borah P, Abed SN, Klotz K-N. Medicinal chemistry and therapeutic potential of agonists, antagonists and allosteric modulators of A1 adenosine receptor: current status and perspectives. Curr Pharm Des. 2019;25:2697–715. https://doi.org/10.2174/1381612825666190716100509.CrossRefPubMed

25.

Yan L, Burbiel JC, Maaß A, Müller CE. Adenosine receptor agonists: from basic medicinal chemistry to clinical development. Expert Opin Emerg Drugs. 2003;8:537–76. https://doi.org/10.1517/14728214.8.2.537.CrossRefPubMed

26.

Klotz KN. Adenosine receptors and their ligands. Naunyn Schmiedebergs Arch Pharmacol. 2000;362:382–91. https://doi.org/10.1007/s002100000315.CrossRefPubMed

27.

Tosh DK, Phan K, Gao ZG, Gakh AA, Xu F, Deflorian F, Abagyan R, Stevens RC, Jacobson KA, Katritch V. Optimization of adenosine 5’-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment screening. J Med Chem. 2012;55:4297–308. https://doi.org/10.1021/jm300095s.CrossRefPubMedPubMedCentral

28.

Bogatko K, Poleszak E, Szopa A, Wyska E, Wlaź P, Świąder K, Wlaź A, Doboszewska U, Rojek K, Serefko A. The influence of selective A1 and A2A receptor antagonists on the antidepressant-like activity of moclobemide, venlafaxine and bupropion in mice. J Pharm Pharmacol. 2018;70:1200–8. https://doi.org/10.1111/jphp.12954.CrossRefPubMed

29.

Müller CE, Jacobson KA. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta - Biomembr. 1808;2011:1290–308. https://doi.org/10.1016/j.bbamem.2010.12.017.CrossRef

30.

Hocher B. Adenosine A1 receptor antagonists in clinical research and development. Kidney Int. 2010;78:438–45. https://doi.org/10.1038/ki.2010.204.CrossRefPubMed

31.

Moro S, Gao ZG, Jacobson KA, Spalluto G. Progress in the pursuit of therapeutic adenosine receptor antagonists. Med Res Rev. 2006;26:131–59. https://doi.org/10.1002/med.20048.CrossRefPubMedPubMedCentral

32.

Scheiff AB, Yerande SG, El-Tayeb A, Li W, Inamdar GS, Vasu KK, Sudarsanam V, Müller CE. 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorganic Med Chem. 2010;18:2195–203. https://doi.org/10.1016/j.bmc.2010.01.072.CrossRef

33.

Muller CE. A1-adenosine receptor antagonists. Expert Opin Ther Pat. 1997;7:419–40. https://doi.org/10.1517/13543776.7.5.419.CrossRef

34.

Novitskiy SV, Ryzhov S, Zaynagetdinov R, Goldstein AE, Huang Y, Tikhomirov OY, Blackburn MR, Biaggioni I, Carbone DP, Feoktistov I, Dikov MM. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood. 2008;112:1822–31. https://doi.org/10.1182/blood-2008-02-136325.CrossRefPubMedPubMedCentral

35.

Haskó G, Pacher P. Regulation of macrophage function by adenosine. Arterioscler Thromb Vasc Biol. 2012;32:865–9. https://doi.org/10.1161/ATVBAHA.111.226852.CrossRefPubMedPubMedCentral

36.

Boyce BF. Advances in the regulation of osteoclasts and osteoclast functions. J Dent Res. 2013;92:860–7. https://doi.org/10.1177/0022034513500306.CrossRefPubMedPubMedCentral

37.

He W, Mazumder A, Wilder T, Cronstein BN. Adenosine regulates bone metabolism via A1, A2A, and A2B receptors in bone marrow cells from normal humans and patients with multiple myeloma. FASEB J. 2013;27:3446–54. https://doi.org/10.1096/fj.13-231233.CrossRefPubMedPubMedCentral

38.

He W, Cronstein BN. Adenosine A1 receptor regulates osteoclast formation by altering TRAF6/TAK1 signaling. Purinergic Signal. 2012;8:327–37. https://doi.org/10.1007/s11302-012-9292-9.CrossRefPubMedPubMedCentral

39.

Kara FM, Chitu V, Sloane J, Axelrod M, Fredholm BB, Stanley ER, Cronstein BN. Adenosine A1 receptors (A1Rs) play a critical role in osteoclast formation and function. FASEB J. 2010;24:2325–33. https://doi.org/10.1096/fj.09-147447.CrossRefPubMedPubMedCentral

40.

He W, Wilder T, Cronstein BN. Rolofylline, an adenosine A1 receptor antagonist, inhibits osteoclast differentiation as an inverse agonist. Br J Pharmacol. 2013;170:1167–76. https://doi.org/10.1111/bph.12342.CrossRefPubMedPubMedCentral

41.

Kara FM, Doty SB, Boskey A, Goldring S, Zaidi M, Fredholm BB, Cronstein BN. Adenosine A1 receptors regulate bone resorption in mice: Adenosine A1 receptor blockade or deletion increases bone density and prevents ovariectomy-induced bone loss in adenosine A1 receptor-knockout mice. Arthritis Rheum. 2010;62:534–41. https://doi.org/10.1002/art.27219.CrossRefPubMedPubMedCentral

42.

Merrill JT, Shen C, Schreibman D, Coffey D, Zakharenko O, Fisher R, Lahita RG, Salmon J, Cronstein BN. Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: a mechanism for methotrexate-induced nodulosis in rheumatoid arthritis. Arthritis Rheum. 1997;40:1308–15. https://doi.org/10.1002/art.16.CrossRefPubMed

43.

Eudy BJ, da Silva RP. Systematic deletion of adenosine receptors reveals novel roles in inflammation and pyroptosis in THP-1 macrophages. Mol Immunol. 2021;132:1–7. https://doi.org/10.1016/j.molimm.2021.01.018.CrossRefPubMed

44.

Tsutsui S, Schnermann J, Noorbakhsh F, Henry S, Yong VW, Winston BW, Warren K, Power C. A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. J Neurosci. 2004;24:1521–9. https://doi.org/10.1523/JNEUROSCI.4271-03.2004.CrossRefPubMedPubMedCentral

45.

Koszałka P, Gołuńska M, Urban A, Stasiłojć G, Stanisławowski M, Majewski M, Składanowski AC, Bigda J. Specific activation of A3, A2a and A1 adenosine receptors in CD73-knockout mice affects B16F10 melanoma growth, neovascularization, angiogenesis and macrophage infiltration. PLoS ONE. 2016;11:1–16. https://doi.org/10.1371/journal.pone.0151420.CrossRef

46.

Eljaszewicz A, Wiese M, Helmin-Basa A, Jankowski M, Gackowska L, Kubiszewska I, Kaszewski W, Michalkiewicz J, Zegarski W. Collaborating with the enemy: function of macrophages in the development of neoplastic disease. Mediators Inflamm. 2013. https://doi.org/10.1155/2013/831387.CrossRefPubMedPubMedCentral

47.

Le Vraux V, Chen YL, Masson I, De Sousa M, Giroud JP, Florentin I, Chauvelot-Moachon L. Inhibition of human monocyte Tnf production by adenosine receptor agonists. Life Sci. 1993;52:1917–24. https://doi.org/10.1016/0024-3205(93)90632-d.CrossRefPubMed

48.

Haskó G, Szabó C, Németh ZH, Kvetan V, Pastores SM, Vizi ES. Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol. 1996;157:4634–40.PubMed

49.

Hona W-M, Moochhala S, Khoo H-E. Adenosine and its receptor agonists potentiate nitric oxide synthase expression induced by lipopolysaccharide in RAW 264.7 murine macrophages. Life Sci. 1997;60:1327–35. https://doi.org/10.1016/s0024-3205(97)00078-7.CrossRef

50.

Zídek Z, Kmoníčková E, Holý A. Involvement of adenosine A 1 receptors in upregulation of nitric oxide by acyclic nucleotide analogues. Eur J Pharmacol. 2004;501:79–86. https://doi.org/10.1016/j.ejphar.2004.08.031.CrossRefPubMed

51.

Joya A, Ardaya M, Montilla A, Garbizu M, Plaza-García S, Gómez-Vallejo V, Padro D, Gutiérrez JJ, Rios X, Ramos-Cabrer P, Cossío U, Pulagam KR, Higuchi M, Domercq M, Cavaliere F, Matute C, Llop J, Martín A. In vivo multimodal imaging of adenosine A1 receptors in neuroinflammation after experimental stroke. Theranostics. 2020;11:410–25. https://doi.org/10.7150/thno.51046.CrossRef

52.

Akhtari M, Zargar SJ, Mahmoudi M, Vojdanian M, Rezaeimanesh A, Jamshidi A. Ankylosing spondylitis monocyte-derived macrophages express increased level of A2A adenosine receptor and decreased level of ectonucleoside triphosphate diphosphohydrolase-1 (CD39), A1 and A2B adenosine receptors. Clin Rheumatol. 2018;37:1589–95. https://doi.org/10.1007/s10067-018-4055-9.CrossRefPubMed

53.

Johnston JB, Silva C, Gonzalez G, Holden J, Warren KG, Metz LM, Power C. Diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis. Ann Neurol. 2001;49:650–8. https://doi.org/10.1002/ana.1007.CrossRefPubMed

54.

Versluis M, Van Den Berge M, Timens W, Luijk B, Rutgers B, Lammers JWJ, Postma DS, Hylkema MN. Allergen inhalation decreases adenosine receptor expression in sputum and blood of asthma patients. Allergy. 2008;63:1186–94. https://doi.org/10.1111/j.1398-9995.2008.01735.x.CrossRefPubMed

55.

Roberta Rose F, Hirschhorn RE, Weissmann G, Cronstein BN. Adenosine promotes neutrophil chemotaxis. J Exp Med. 1988;167:1186–94. https://doi.org/10.1084/jem.167.3.1186.CrossRef

56.

Cronstein BN, Daguma L, Nichols D, Hutchison AJ, Williams M. The adenosine/neutrophil paradox resolved: human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O-2 generation, respectively. J Clin Invest. 1990;85:1150–7. https://doi.org/10.1172/JCI114547.CrossRefPubMedPubMedCentral

57.

Xu X, Zheng S, Xiong Y, Wang X, Qin W, Zhang H, Sun B. Adenosine effectively restores endotoxin-induced inhibition of human neutrophil chemotaxis via A1 receptor-p38 pathway. Inflamm Res. 2017;66:353–64. https://doi.org/10.1007/s00011-016-1021-3.CrossRefPubMed

58.

Bong GW, Rosengren S, Firestein GS. Spinal cord adenosine receptor stimulation in rats inhibits peripheral neutrophil accumulation: the Role of N-methyl-D-aspartate receptors. J Clin Invest. 1996;98:2779–85. https://doi.org/10.1172/JCI119104.CrossRefPubMedPubMedCentral

59.

Ozacmak VH, Sayan H. Pretreatment with adenosine and adenosine A1 receptor agonist protects againts intestinal ischemia-reperfusion injury in rat. World J Gastroenterol. 2007;13:538–47. https://doi.org/10.3748/wjg.v13.i4.538.CrossRefPubMedPubMedCentral

60.

Fernandez LG, Sharma AK, LaPar DJ, Kron IL, Laubach VE. Adenosine A1 receptor activation attenuates lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg. 2013;145:1654–9. https://doi.org/10.1016/j.jtcvs.2013.01.006.Adenosine.CrossRefPubMedPubMedCentral

61.

Gazoni LM, Walters DM, Unger EB, Linden J, Kron IL, Laubach VE. Activation of A1, A2A, or A3 adenosine receptors attenuates lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg. 2010;140:440–6. https://doi.org/10.1016/j.jtcvs.2010.03.002.CrossRefPubMedPubMedCentral

62.

Park SW, Kim JY, Ham A, Brown KM, Kim M, D’Agati VD, Lee HT. A1 adenosine receptor allosteric enhancer PD-81723 protects against renal ischemia-reperfusion injury. Am J Physiol-Ren Physiol. 2012. https://doi.org/10.1152/ajprenal.00157.2012.CrossRef

63.

Lee HT, Xu H, Nasr SH, Schnermann J, Emala CW. A1 adenosine receptor knockout mice exhibit increased renal injury following ischemia and reperfusion. Am J Physiol - Ren Physiol. 2004;286:298–306. https://doi.org/10.1152/ajprenal.00185.2003.CrossRef

64.

Kim J, Kim M, Song JH, Thomas Lee H. Endogenous A1 adenosine receptors protect against hepatic ischemia reperfusion injury in mice. Liver Transplant. 2007;14:845–54. https://doi.org/10.1002/lt.21432.CrossRef

65.

Forman MB, Vitola JV, Velasco CE, Murray JJ, Dubey RK, Jackson EK. Sustained reduction in myocardial reperfusion injury with an adenosine receptor antagonist: possible role of the neutrophil chemoattractant response. J Pharmacol Exp Ther. 2000;292:929–38.PubMed

66.

Cronstein BN, Levin RI, Philips M, Hirschhorn R, Abramson SB, Weissmann G. Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J Immunol. 1992;148:2201–6.PubMed

67.

Felsch A, Stöcker K, Borchard U. Phorbol ester-stimulated adherence of neutrophils to endothelial cells is reduced by adenosine A2 receptor agonists. J Immunol. 1995;155:333–8.PubMed

68.

Barletta KE, Ley K, Mehrad B. Regulation of neutrophil function by adenosine. Arterioscler Thromb Vasc Biol. 2012;32:856–64. https://doi.org/10.1161/ATVBAHA.111.226845.CrossRefPubMedPubMedCentral

69.

Bhalla M, Simmons SR, Abamonte A, Herring SE, Roggensack SE, Bou Ghanem EN. Extracellular adenosine signaling reverses the age-driven decline in the ability of neutrophils to kill Streptococcus pneumoniae. Aging Cell. 2020;19:1–12. https://doi.org/10.1111/acel.13218.CrossRef

70.

Salmon JE, Cronstein BN. Fc gamma receptor-mediated functions in neutrophils are modulated by adenosine receptor occupancy. A1 receptors are stimulatory and A2 receptors are inhibitory. J Immunol. 1990;145:2235–40.PubMed

71.

Zalavary S, Stendahl O. The role of cyclic AMP, calcium and filamentous actin in adenosine modulation of Fc receptor-mediated phagocytosis in human neutrophils. Biochim Biophys Acta. 1994;1222:249–56. https://doi.org/10.1016/0167-4889(94)90176-7.CrossRefPubMed

72.

Kälvegren H, Fridfeldt J, Bengtsson T. The role of plasma adenosine deaminase in chemoattractant-stimulated oxygen radical production in neutrophils. Eur J Cell Biol. 2010;89:462–7. https://doi.org/10.1016/j.ejcb.2009.12.004.CrossRefPubMed

73.

Gardner A, de Mingo Pulido Á, Ruffell B. Dendritic cells and their role in immunotherapy. Front Immunol. 2020;11:1–14. https://doi.org/10.3389/fimmu.2020.00924.CrossRef

74.

Reizis B. Plasmacytoid dendritic cells: development, regulation, and function. Immunity. 2019;50:37–50. https://doi.org/10.1016/j.immuni.2018.12.027.CrossRefPubMedPubMedCentral

75.

Zhou B, Lawrence T, Liang Y. The role of plasmacytoid dendritic cells in cancers. Front Immunol. 2021;12:1–10. https://doi.org/10.3389/fimmu.2021.749190.CrossRef

76.

Schnurr M, Toy T, Shin A, Hartmann G, Rothenfusser S, Soellner J, Davis ID, Cebon J, Maraskovsky E. Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood. 2004;103:1391–7. https://doi.org/10.1182/blood-2003-06-1959.CrossRefPubMed

77.

Panther E, Idzko M, Herouy Y, Rheinen H, Gebicke-HAERTER PJ, Mrowietz U, Dichmann S, Norgauer J. Expression and function of adenosine receptors in human dendritic cells. FASEB J. 2001;15:1963–70. https://doi.org/10.1096/fj.01-0169com.CrossRefPubMed

78.

Yasui K, Kondo Y, Wada T, Yashiro M, Tsuge M, Morishima T. Theophylline inhibits the differentiation of human monocyte into dendritic cell potentially via adenosine receptor antagonism. Clin Exp Allergy. 2009;39:1857–65. https://doi.org/10.1111/j.1365-2222.2009.03365.x.CrossRefPubMed

79.

Desrosiers MD, Cembrola KM, Fakir MJ, Stephens LA, Jama FM, Shameli A, Mehal WZ, Santamaria P, Shi Y. Adenosine deamination sustains dendritic cell activation in inflammation. J Immunol. 2007;179:1884–92. https://doi.org/10.4049/jimmunol.179.3.1884.CrossRefPubMed

80.

Chen L, Fredholm BB, Jondal M. Adenosine, through the A1 receptor, inhibits vesicular MHC class I cross-presentation by resting DC. Mol Immunol. 2008;45:2247–54. https://doi.org/10.1016/j.molimm.2007.11.016.CrossRefPubMed

81.

Prinz M, Jung S, Priller J. Microglia biology: one century of evolving concepts. Cell. 2019;179:292–311. https://doi.org/10.1016/j.cell.2019.08.053.CrossRefPubMed

82.

Ohsawa K, Kohsaka S. Dynamic motility of microglia: purinergic modulation of microglial movement in the normal and pathological brain. Glia. 2011;59:1793–9. https://doi.org/10.1002/glia.21238.CrossRefPubMed

83.

Nayak D, Roth TL, McGavern DB. Microglia development and function. Annu Rev Immunol. 2014;32:367–402. https://doi.org/10.1146/annurev-immunol-032713-120240.CrossRefPubMedPubMedCentral

84.

Luongo L, Guida F, Imperatore R, Napolitano F, Gatta L, Cristino L, Giordano C, Siniscalco D, Di Marzo V, Bellini G, Petrelli R, Cappellacci L, Usiello A, de Novellis V, Rossi F, Maione S. The A1 adenosine receptor as a new player in microglia physiology. Glia. 2014;62:122–32. https://doi.org/10.1002/glia.22592.CrossRefPubMed

85.

Ohsawa K, Sanagi T, Nakamura Y, Suzuki E, Inoue K, Kohsaka S. Adenosine A3 receptor is involved in ADP-induced microglial process extension and migration. J Neurochem. 2012;121:217–27. https://doi.org/10.1111/j.1471-4159.2012.07693.x.CrossRefPubMed

86.

Wolf SA, Boddeke HWGM, Kettenmann H. Microglia in physiology and disease. Annu Rev Physiol. 2017;79:619–43. https://doi.org/10.1146/annurev-physiol-022516-034406.CrossRefPubMed

87.

Marucci G, Dal Ben D, Lambertucci C, Navia AM, Spinaci A, Volpini R, Buccioni M. Combined therapy of A1AR agonists and A2AAR antagonists in neuroinflammation. Molecules. 2021;26:1188. https://doi.org/10.3390/molecules26041188.CrossRefPubMedPubMedCentral

88.

Gomes CV, Kaster MP, Tomé AR, Agostinho PM, Cunha RA. Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. Biochim Biophys Acta - Biomembr. 1808;2011:1380–99. https://doi.org/10.1016/j.bbamem.2010.12.001.CrossRef

89.

Haselkorn ML, Shellington DK, Jackson EK, Vagni VA, Janesko-Feldman K, Dubey RK, Gillespie DG, Cheng D, Bell MJ, Jenkins LW, Homanics GE, Schnermann J, Kochanek PM. Adenosine A1 receptor activation as a brake on the microglial response after experimental traumatic brain injury in mice. J Neurotrauma. 2010;27:901–10. https://doi.org/10.1089/neu.2009.1075.CrossRefPubMedPubMedCentral

90.

Cipriani R, Villa P, Chece G, Lauro C, Paladini A, Micotti E, Perego C, de Simoni MG, Fredholm BB, Eusebi F, Limatola C. CX3CL1 is neuroprotective in permanent focal cerebral ischemia in rodents. J Neurosci. 2011;31:16327–35. https://doi.org/10.1523/JNEUROSCI.3611-11.2011.CrossRefPubMedPubMedCentral

91.

Catalano M, Lauro C, Cipriani R, Chece G, Ponzetta A, Di Angelantonio S, Ragozzino D, Limatola C. CX3CL1 protects neurons against excitotoxicity enhancing GLT-1 activity on astrocytes. J Neuroimmunol. 2013;263:75–82. https://doi.org/10.1016/j.jneuroim.2013.07.020.CrossRefPubMed

92.

Luongo L, Petrelli R, Gatta L, Giordano C, Guida F, Vita P, Franchetti P, Grifantini M, De Novellis V, Cappellacci L, Maione S. 5’-Chloro-5’-deoxy-(±)-ENBA, a potent and selective adenosine A1 receptor agonist, alleviates neuropathic pain in mice through functional glial and microglial changes without affecting motor or cardiovascular functions. Molecules. 2012;17:13712–26. https://doi.org/10.3390/molecules171213712.CrossRefPubMedPubMedCentral

93.

Gebicke-Haerter PJ, Christoffel F, Timmer J, Northoff H, Berger M, Van Calker D. Both adenosine A1- and A2-receptors are required to stimulate microglial proliferation. Neurochem Int. 1996;29:37–42. https://doi.org/10.1016/0197-0186(95)00137-9.CrossRefPubMed

94.

Saze Z, Schuler PJ, Hong CS, Cheng D, Jackson EK, Whiteside TL. Adenosine production by human B cells and B cell-mediated suppression of activated T cells. Blood. 2013;122:9–18. https://doi.org/10.1182/blood-2013-02-482406.CrossRefPubMedPubMedCentral

95.

Figueiró F, Muller L, Funk S, Jackson EK, Battastini AMO, Whiteside TL. Phenotypic and functional characteristics of CD39high human regulatory B cells (Breg). Oncoimmunology. 2016;5: e1082703. https://doi.org/10.1080/2162402X.2015.1082703.CrossRefPubMedPubMedCentral

96.

Mei HF, Poonit N, Zhang YC, Ye CY, Cai HL, Yu CY, Zhou YH, Bei Wu B, Cai J, Cai XH. Activating adenosine A1 receptor accelerates PC12 cell injury via ADORA1/PKC/KATP pathway after intermittent hypoxia exposure. Mol Cell Biochem. 2018;446:161–70. https://doi.org/10.1007/s11010-018-3283-2.CrossRefPubMed

Title: The role of adenosine A1 receptor on immune cells
Authors: Lingyu Zhong
Qiao Peng
Xun Zeng
Publication date: 05-09-2022
Publisher: Springer International Publishing
Published in: Inflammation Research / Issue 10-11/2022
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-022-01607-w

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The role of adenosine A₁ receptor on immune cells

Abstract

Background

Materials and methods

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Materials and methods

Conclusion

Please log in to get access to this content

Other articles of this Issue 10-11/2022

CD20+ T cells: an emerging T cell subset in human pathology

IL-25 directly modulates adipocyte function and inflammation through the regulation of adiponectin

The HMGB1-RAGE axis induces apoptosis in acute respiratory distress syndrome through PERK/eIF2α/ATF4-mediated endoplasmic reticulum stress

Targeting ACE2 as a potential prophylactic strategy against COVID-19-induced exacerbation of chronic kidney disease

Review: the role of GSDMD in sepsis

Comprehensive comparison of the prognostic value of systemic inflammation biomarkers for cancer cachexia: a multicenter prospective study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page